CLINICAL STUDY RESULTS
The SARCLISA Phase 3 study
SARCLISA is the first and only treatment to be approved based on a large Phase 3 study when given together with Pomalyst® (pomalidomide) and dexamethasone (Pd)
SARCLISA was studied when given together with Pd and compared to Pd alone. 307 people with relapsed refractory multiple myeloma took part in the study. 154 people received SARCLISA + Pd and 153 people received Pd alone. People in the study had at least 2 prior treatments for multiple myeloma, including Revlimid® (lenalidomide) and a proteasome inhibitor (PI).
The goals of the SARCLISA study
- The main goal of the SARCLISA study was to measure the amount of time a person lives with multiple myeloma without it getting worse. This is commonly referred to as progression-free survival
- Another goal of the study was to measure how many people responded positively to treatment. A positive response to treatment means a decrease in the number of myeloma cells in the bone marrow. Response to treatment is determined by tests performed after treatment has begun
You are unique — and so is your Multiple Myeloma
SARCLISA was studied in a wide variety of people with relapsed refractory Multiple Myeloma
About people in the SARCLISA study
Ages ranged from
36 to 86 years old
173 people had previously received stem cell transplant for their multiple myeloma and 134 had not
More than 90% of people had
previously stopped responding
to treatment with Revlimid®
Some people in the study had other medical
conditions in addition to relapsed refractory multiple myeloma
32 people had a history of
asthma or chronic obstructive
pulmonary disease (COPD)
104 people had impaired
kidney function
See the results of the SARCLISA Phase 3 study.
A proven response to relapsed refractory Multiple Myeloma
SARCLISA was proven, when given together with Pomalyst® (pomalidomide) and dexamethasone (Pd), to help extend the time people live without their Multiple Myeloma getting worse
In the study, people receiving SARCLISA + Pd went a median of 11.5 months without their multiple myeloma getting worse compared to a median of 6.5 months for people receiving Pd alone.
Significantly more people responded to SARCLISA + Pd
More people responded to treatment with SARCLISA + Pd compared to Pd alone
Among people who responded to treatment, the median time it took to respond was 35 days for people treated with SARCLISA + Pd compared to 58 days for people treated with Pd alone
*This measure indicates a reduction in risk of a person’s multiple myeloma getting worse or that person passing away.
CareASSIST helps eligible patients with access and support for SARCLISA.